This study includes 47 normal subjects and 25 hemophilia B patients without inhibitor(s), showing different factor IX coagulant activity and antigen levels. Genomic DNA, digested with various restriction endonucleases, was hybridized with two different factor IX probes, ie, the cDNA and the subgenomic probe for the intragenic TaqI polymorphic site. cDNA restriction patterns suggest absence of gross rearrangements and/or deletions in all hemophilic patients. The frequency of the X chromosome bearing the TaqI polymorphic site is 0.32 +/- 0.09 in hemophilic subjects v 0.36 +/- 0.06 in normal control subjects, the latter value being comparable to that reported for the normal British population. No association between this polymorphism and hemophilia B variants has been observed, thus indicating that a wide spectrum of mutations underlies this blood-clotting disorder and particularly each of its variants.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Genetic Diagnosis and Prenatal Diagnosis of a Rare FVIII Family With Haemophilia A.
J Cell Mol Med
December 2024
Reproductive Genetics Department, Hebei General Hospital, Shijiazhuang, Hebei, China.
Article Synopsis
- - The study focused on identifying genetic variations causing haemophilia A within a unique family, using advanced techniques like DHPLC and PCR for diagnosis.
- - Comprehensive clinical data and laboratory tests revealed the proband's significantly prolonged activated partial prothrombin time (APTT) and low clotting factor VIII activity, suggesting serious coagulation issues.
- - A rare pathogenic mutation involving a 226 bp insertion in the F8 gene was discovered, highlighting the importance of using multiple experimental approaches for effective genetic diagnosis of haemophilia A.
Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study.
Blood Adv
November 2024
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Diagnostic boundaries between immune thrombocytopenia (ITP) and other thrombocytopenic states such as thrombocytopenic myelodysplastic syndromes, may be difficult to establish, and the detection of somatic mutations by next generation sequencing (NGS) may be of aid. Here we aimed at characterizing the prevalence and clinical significance of clonal hematopoiesis in ITP. In this multicentric retrospective observational study we enrolled 167 adult ITP patients, followed at 13 centers in Italy, UK, and USA.
View Article and Find Full Text PDFStudy on the Mutation of FⅨ Gene in 31 Patients with Type B Hemophilia.
Clin Appl Thromb Hemost
August 2024
Department of Clinical lab, Zhenhai Street Community Health Service Center, Licheng District, Putian, 351100, Fujian, China.
Article Synopsis
- Hemophilia B is a genetic bleeding disorder caused by mutations in the FⅨ gene, which severely impacts blood coagulation.
- The study identified mutations in this gene by analyzing DNA from 31 HB patients, using PCR and sequencing techniques, and discovered a hotspot for mutations in the CpG region.
- The findings contribute to the global understanding of FⅨ mutations, highlight differences in the Chinese population, and pave the way for future gene therapy developments.
Gene-Gene Interaction Between Factor- and Genes in Cerebral Venous Thrombosis: The BEAST Study.
Neurology
June 2024
From the Institute of Cardiovascular Research Royal Holloway (G.K.-D., P.S.), University of London (ICR2UL), United Kingdom; Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico (I.M., S.M.P., M.A., P.B., E.P.), A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Moncucco Hospital Group (I.M., E.G.), Lugano, Switzerland; Atherosclerosis and Thrombosis Unit (E.G., G.F., D.C.), I.R.C.C.S. Fondazione "Casa Sollievo della Sofferenza", S. Giovanni Rotondo; Medical and Surgical Department (E.G.), University of Foggia, Italy; Department of Obstetrics (E.G.), Gynaecology and Perinatal Medicine, First Sechenov University, Moscow, Russia; Neurology (S.H., J.P., E.H., T.T.), Helsinki University Hospital and University of Helsinki, Finland; Department of Clinical Neuroscience (E.L., K.J., T.T.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Department of Neurology (E.L., K.J., T.T.), Sahlgrenska University Hospital, Gothenburg, Sweden; Medical Genetics (M. Margaglione, R.S.), Department of Clinical and Experimental Medicine, University of Foggia, Italy; Normandy University (V.L.C.D.), UNIROUEN, INSERM U1096, Rouen University Hospital, Vascular Hemostasis Unit and INSERM CIC-CRB 1404; Department of Neurology (A.B.T.), Rouen University Hospital, France; Neurology Unit (M.Z.), Stroke Unit, Azienda Unità Sanitaria Locale-IRCCS of Reggio Emilia; Department of Clinical and Experimental Medicine (M. Mancuso), Neurological Institute, University of Pisa, Italy; UMC Utrecht Brain Center (Y.M.R.), Department of Neurology and Neurosurgery, University Medical Center Utrecht, the Netherlands; Department of Neurology (B.B.W.), University of Virginia, Charlottesville, VA; Department of Neurology (J.J.M., A.T.), University of Utah, Salt Lake City; Department of Neurology (S.Z., M.C.B., J.M.C.), Amsterdam University Medical Centers, location AMC, Amsterdam Neuroscience, University of Amsterdam, the Netherlands; Department of Neurosciences (R.L.), Experimental Neurology, KU Leuven-University of Leuven; VIB Center for Brain & Disease Research; Department of Neurology, University Hospitals Leuven, Belgium; Department of Pathophysiology and Transplantation (E.P.), Università degli Studi di Milano, Milan; Department of Clinical and Experimental Sciences (P. Costa), Neurology Clinic; Division of Biology and Genetics (M.C.), Department of Molecular and Translational Medicine, University of Brescia, Italy; Stroke Center (D.A.D.S.), Centro Hospitalar Universitário Lisboa Central; CEEM and Institute of Anatomy (D.A.D.S.), Faculdade de Medicina; Instituto de Medicina Molecular João Lobo Antunes (D.A.D.S., J.M.F.), Universidade de Lisboa; Department of Neurosciences (S.G.R., P. Canhao), Hospital of Santa Maria, University of Lisbon, Portugal; Stroke Clinic (A.A.), National Institute of Neurology and Neurosurgery Manuel Velasco Suarez, Mexico City; Department of Neurology (K.S.), University of Athens School of Medicine, Eginition Hospital, Athens, Greece; McMaster University (A.H., R.D., G.P.), Pathology and Molecular Medicine, Population Health Research Institute and Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Medicine and Surgery (A.P.), University of Parma, Stroke Care Program, Department of Emergency, Parma University Hospital, Italy; Stroke Division (V.N.T.), Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia; and Department of Clinical Neuroscience (P.S.), Imperial College Healthcare NHS Trust, London, United Kingdom.
Article Synopsis
- Gene-gene interactions are believed to play a significant role in the development of multifactorial diseases like cerebral venous thrombosis (CVT), highlighting potential causes of unexplained heritability.
- A study involving 882 CVT patients and 1,205 control participants found that specific gene variants significantly increased the likelihood of developing CVT, particularly when individuals had certain blood types.
- The research concluded that the interactions between specific genes could raise the risk of CVT by as much as 14 times, underscoring the importance of understanding these genetic factors in disease etiology.
Comprehensive genomic filtering algorithm to expose the cause of skewed X chromosome inactivation. The proof of concept in female haemophilia expression.
J Med Genet
July 2024
Laboratorio de Genética Molecular de la Hemofilia, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina
Background: Exploring the expression of X linked disorders like haemophilia A (HA) in females involves understanding the balance achieved through X chromosome inactivation (XCI). Skewed XCI (SXCI) may be involved in symptomatic HA carriers. We aimed to develop an approach for dissecting the specific cause of SXCI and verify its value in HA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!